RESUMO
BACKGROUND: The applicability of ultra-hypofractionated (ultra-HF) whole-breast irradiation (WBI) remains unknown in Japanese women. This study aimed to evaluate the safety and efficacy of this approach among Japanese women and report the results of an interim analysis performed to assess acute adverse events (AEs) and determine whether it was safe to continue this study. METHODS: We enrolled Japanese women with invasive breast cancer or ductal carcinoma in situ who had undergone breast-conserving surgery, were aged ≥ 40 years, had pathological stages of Tis-T3 N0-N1, and had negative surgical margins. Ultra-HF-WBI was delivered at 26 Gy in five fractions over one week. When the number of enrolled patients reached 28, patient registration was paused for three months. The endpoint of the interim analysis was the proportion of acute AEs of grade ≥ 2 (Common Terminology Criteria for Adverse Events v5.0) within three months. RESULTS: Of the 28 patients enrolled from seven institutes, 26 received ultra-HF-WBI, and 2 were excluded due to postoperative infections. No AEs of grade ≥ 3 occurred. One patient (4%) experienced grade 2 radiation dermatitis, and 18 (69%) had grade 1 radiation dermatitis. The other acute grade 1 AEs experienced were skin hyperpigmentation (n = 10, 38%); breast pain (n = 4, 15%); superficial soft tissue fibrosis (n = 3, 12%); and fatigue (n = 1, 4%). No other acute AEs of grade ≥ 2 were detected. CONCLUSIONS: Acute AEs following ultra-HF-WBI were within acceptable limits among Japanese women, indicating that the continuation of the study was appropriate.
Assuntos
Neoplasias da Mama , Mastectomia Segmentar , Humanos , Feminino , Neoplasias da Mama/cirurgia , Neoplasias da Mama/radioterapia , Neoplasias da Mama/patologia , Mastectomia Segmentar/efeitos adversos , Pessoa de Meia-Idade , Idoso , Japão/epidemiologia , Adulto , Hipofracionamento da Dose de Radiação , Carcinoma Intraductal não Infiltrante/cirurgia , Carcinoma Intraductal não Infiltrante/patologia , Carcinoma Intraductal não Infiltrante/radioterapia , Radioterapia Adjuvante/efeitos adversos , Radioterapia Adjuvante/métodos , Idoso de 80 Anos ou maisRESUMO
BACKGROUND/AIM: Radiotherapy (RT) outcomes are generally reported based on stage, patient background, and concomitant chemotherapy. This study aimed to investigate the effects of the prescribed dose to gross tumor volume (GTV) and the calculation algorithm on local control in definitive RT for head and neck (H&N) cancers using follow-up images after RT. PATIENTS AND METHODS: This study included 154 patients with H&N cancers treated by Volumetric Modulated Arc Therapy at the Kobe City Medical Center General Hospital. Patients were classified into those receiving definitive RT (70 Gy of irradiation) and those not receiving it. Follow-up images were used to categorize the patients into the responders and non-responders groups. In the non-responders group, follow-up images were imported into the treatment planning system, and the contours of the residual or recurrent areas (local failure) were extracted and fused with computed tomography-simulated images for treatment planning. Dose evaluation parameters included maximum dose, dose administered to 1% of the volume, dose administered to 50% of the volume, dose administered to 99% of the volume (D99%), and minimum dose (Dmin) administered to the GTV. The doses to the GTV were compared between responders and non-responders. RESULTS: D99% exhibited significant differences between local failure and responders and between local failure and non-responders. Dmin showed significant differences between responders and non-responders and between responders and local failure. CONCLUSION: This study emphasizes the importance of verifying dose distribution in all slices of treatment planning, highlighting the need for precise assessment of the dose to the GTV in head and neck cancers.
Assuntos
Neoplasias de Cabeça e Pescoço , Radioterapia Conformacional , Radioterapia de Intensidade Modulada , Humanos , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/métodos , Neoplasias de Cabeça e Pescoço/radioterapia , Radioterapia Conformacional/métodos , Radioterapia de Intensidade Modulada/métodosRESUMO
PURPOSE: The UK-FAST-Forward study showed that ultra-hypofractionated whole-breast irradiation (ultra-HF-WBI) involving five fractions of 26 Gy radiation over 1 week was not inferior to HF-WBI. However, it is not used in Japan due to safety concerns. In April 2022, we commenced a multi-institutional, single-arm, phase II trial. Our aim is to confirm the safety of ultra-HF-WBI after breast-conserving surgery (BCS) for breast cancer in Japanese women. METHOD: We plan to enroll 98 patients from 13 institutions. The primary endpoint is the proportion of late adverse events of grades ≥2 within 3 years. DISCUSSION: We believe that this highly promising clinical study can positively impact the Japanese guidelines for breast cancer treatment. The results will help us decide whether or not ultra-HF-WBI can be used as a more convenient alternative to WBI. REGISTRATION NUMBER AND DATE: This trial was registered in the UMIN Clinical Trials Registry (UMIN000047080) on March 4, 2022.
Assuntos
Neoplasias da Mama , Radioterapia (Especialidade) , Feminino , Humanos , Neoplasias da Mama/radioterapia , Neoplasias da Mama/cirurgia , Fracionamento da Dose de Radiação , Japão , Mastectomia Segmentar , Radioterapia Adjuvante/efeitos adversos , Radioterapia Adjuvante/métodosRESUMO
PURPOSE: To quantify dose delivery errors for high-dose-rate image-guided brachytherapy (HDR-IGBT) using an independent end-to-end dose delivery quality assurance test at multiple institutions. The novelty of our study is that this is the first multi-institutional end-to-end dose delivery study in the world. MATERIALS AND METHODS: The postal audit used a polymer gel dosimeter in a cylindrical acrylic container for the afterloading system. Image acquisition using computed tomography, treatment planning, and irradiation were performed at each institution. Dose distribution comparison between the plan and gel measurement was performed. The percentage of pixels satisfying the absolute-dose gamma criterion was reviewed. RESULTS: Thirty-five institutions participated in this study. The dose uncertainty was 3.6% ± 2.3% (mean ± 1.96σ). The geometric uncertainty with a coverage factor of kâ¯=â¯2 was 3.5 mm. The tolerance level was set to the gamma passing rate of 95% with the agreement criterion of 5% (global)/3 mm, which was determined from the uncertainty estimation. The percentage of pixels satisfying the gamma criterion was 90.4% ± 32.2% (mean ± 1.96σ). Sixty-six percent (23/35) of the institutions passed the verification. Of the institutions that failed the verification, 75% (9/12) had incorrect inputs of the offset between the catheter tip and indexer length in treatment planning and 17% (2/12) had incorrect catheter reconstruction in treatment planning. CONCLUSIONS: The methodology should be useful for comprehensively checking the accuracy of HDR-IGBT dose delivery and credentialing clinical studies. The results of our study highlight the high risk of large source positional errors while delivering dose for HDR-IGBT in clinical practices.
Assuntos
Braquiterapia , Humanos , Braquiterapia/métodos , Dosagem Radioterapêutica , Dosímetros de Radiação , Catéteres , Tomografia Computadorizada por Raios X , Radiometria/métodos , Imagens de FantasmasRESUMO
Dose verification for a gimbal-mounted image-guided radiotherapy system, Vero4DRT (Mitsubishi Heavy Industries Ltd., Tokyo, Japan) is usually carried out by pretreatment measurement. Independent verification calculations using Monte Carlo methods for Vero4DRT have been published. As the Clarkson method is faster and easier to use than measurement and Monte Carlo methods, we evaluated the accuracy of an independent calculation verification program and its feasibility as a secondary check for Vero4DRT. Computed tomography (CT)-based dose calculation was performed using a modified Clarkson-based algorithm. In this study, 120 patients' treatment plans were collected in our institute. The treatments were performed using conventional irradiation for lung and prostate, 3-dimensional (3D) conformal stereotactic body radiotherapy (SBRT) for the lung, and intensity-modulated radiation therapy (IMRT) for the prostate. Differences between the treatment planning system (TPS) and the Clarkson-based independent dose verification software were computed, and confidence limits (CLs, mean ± 2 standard deviation %) for Vero4DRT were compared with the CLs for the C-arms linear accelerators in the previous study. The results of the CLs, the conventional irradiation, SBRT, and IMRT showed 2.2 ± 3.5% (CL of the C-arms linear accelerators: 2.4 ± 5.3%), 1.1 ± 1.7% (-0.3 ± 2.0%), 4.8 ± 3.7% (5.4 ± 5.3%), and -0.5 ± 2.5% (-0.1 ± 3.6%) differences, respectively. The dose disagreement between the TPS and CT-based independent dose verification software was less than the 5% action level of American Association of Physicists in Medicine (AAPM) Task Group 114 (TG114). The CLs for the gimbal-mounted Vero4DRT were similar to the deviations for C-arms linear accelerators.
Assuntos
Radioterapia/métodos , Algoritmos , Estudos de Viabilidade , Humanos , Neoplasias Pulmonares/radioterapia , Masculino , Neoplasias da Próstata/radioterapia , Doses de Radiação , Radioterapia/instrumentação , Estudos RetrospectivosRESUMO
PURPOSE: This report covers the first multi-institutional study of independent monitor unit (MU)/dose calculation verification for the CyberKnife, Vero4DRT, and TomoTherapy radiotherapy delivery systems. METHODS: A total of 973 clinical treatment plans were collected from 12 institutions. Commercial software employing the Clarkson algorithm was used for verification after a measurement validation study, and the doses from the treatment planning systems (TPSs) and verification programs were compared on the basis of the mean value⯱â¯two standard deviations. The impact of heterogeneous conditions was assessed in two types of sites: non-lung and lung. RESULTS: The dose difference for all locations was 0.5⯱â¯7.2%. There was a statistically significant difference (Pâ¯<â¯0.01) in dose difference between non-lung (-0.3⯱â¯4.4%) and lung sites (3.5⯱â¯6.7%). Inter-institutional comparisons showed that various systematic differences were associated with the proportion of different treatment sites and heterogeneity correction. CONCLUSIONS: This multi-institutional comparison should help to determine the departmental action levels for CyberKnife, Vero4DRT, and TomoTherapy, as patient populations and treatment sites may vary between the modalities. An action level of ±5% could be considered for intensity-modulated radiation therapy (IMRT), non-IMRT, and volumetric modulated arc radiotherapy using these modalities in homogenous and heterogeneous conditions with a large treatment field applied to a large region of homogeneous media. There were larger systematic differences in heterogeneous conditions with a small treatment field because of differences in heterogeneity correction with the different dose calculation algorithms of the primary TPS and verification program.
Assuntos
Aceleradores de Partículas , Garantia da Qualidade dos Cuidados de Saúde , Planejamento da Radioterapia Assistida por Computador , Algoritmos , Humanos , Pulmão , Garantia da Qualidade dos Cuidados de Saúde/métodos , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/métodos , Radioterapia de Intensidade Modulada/instrumentação , Estudos RetrospectivosRESUMO
PURPOSE: As there have been few reports on quantitative analysis of inter-institutional results for independent monitor unit (MU) verification, we performed a multi-institutional study of verification to show the feasibility of applying the 3-5% action levels used in the U.S. and Europe, and also to show the results of inter-institutional comparisons. METHODS: A total of 5936 fields were collected from 12 institutions. We used commercial software employing the Clarkson algorithm for verification after a validation study of measurement and software comparisons was performed. The doses generated by the treatment planning systems (TPSs) were retrospectively analyzed using the verification software. RESULTS: Mean⯱â¯two standard deviations of all locations were 1.0⯱â¯3.6%. There were larger differences for breast (4.0⯱â¯4.0%) and for lung (2.5⯱â¯5.8%). A total of 80% of the fields with differences over 5% of the action level involved breast and lung targets, with 7.2⯱â¯5.4%. Inter-institutional comparisons showed various systematic differences for field shape for breast and differences in the fields were attributable to differences in reference point placement for lung. The large differences for breast and lung are partially attributable to differences in the methods used to correct for heterogeneity. CONCLUSIONS: The 5% action level may be feasible for verification; however, an understanding of larger differences in breast and lung plans is important in clinical practice. Based on the inter-institutional comparisons, care must be taken when determining an institution-specific action level from plans with different field shape settings and incorrectly placed reference points.
Assuntos
Doses de Radiação , Planejamento da Radioterapia Assistida por Computador/métodos , Radioterapia de Intensidade Modulada , Humanos , Aceleradores de Partículas , Controle de Qualidade , Dosagem Radioterapêutica , Estudos Retrospectivos , SoftwareRESUMO
PURPOSE: No multi-institutional studies of computer-based independent dose calculation have addressed the discrepancies among radiotherapy treatment planning systems (TPSs) and the verification programs for intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). We conducted a multi-institutional study to investigate whether ±5% is a reasonable action level for independent dose calculation for IMRT/VMAT. METHODS: In total, 477 IMRT/VMAT plans for prostate or head and neck (H&N) malignancies were retrospectively analyzed using a modified Clarkson-based commercial verification program. The doses from the TPSs and verification programs were compared using the mean ±1 standard deviation (SD). RESULTS: In the TPS-calculated dose comparisons for prostate and H&N malignancies, the sliding window (SW) technique (-2.5⯱â¯1.8% and -5.3⯱â¯2.6%) showed greater negative systematic differences than the step-and-shoot (S&S) technique (-0.3⯱â¯2.2% and -0.8⯱â¯2.2%). The VMAT dose differences for prostate and H&N malignancies were 0.9⯱â¯1.8% and 1.1⯱â¯3.3%, respectively. The SDs were larger for the H&N plans than for the prostate plans in both IMRT and VMAT. Such plans including more out-of-field control points showed greater systematic differences and SDs. CONCLUSIONS: This study will help individual institutions to establish an action level for agreement between primary calculations and verification for IMRT/VMAT. A local dose difference of ±5% at a point within the planning target volume (above -350â¯HU) may be a reasonable action level.
Assuntos
Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Radioterapia de Intensidade Modulada , Neoplasias de Cabeça e Pescoço/radioterapia , Humanos , Masculino , Neoplasias da Próstata/radioterapia , Planejamento da Radioterapia Assistida por Computador/métodos , Estudos RetrospectivosRESUMO
It is essential for quality assurance to verify the safety of each individual patient's plan in radiation therapy. The tolerance level for independent verification of monitor unit calculations for non-IMRT clinical radiotherapy has been shown in the AAPM TG114. Thus, we investigated the precision of independent MU (dose) verification considering a wedge off-axis calculation and we conducted a study at twelve institutes for independent verification with the wedge off-axis calculation. The results obtained with the wedge off-axis calculation showed better agreement with the treatment planning system calculation results than those without the former calculation in a phantom study and in the patient retrospective study. The confidence limits with the wedge off-axis calculation were 2.2±3.4% and 2.0±4.3% for the plans with a physical wedge and a non-physical wedge in the patient study, respectively. However, the confidence limits were over 5% without the off-axis calculation. From our multi-institutional study, the results suggested that the tolerance level for the wedge off-axis plan would be 5% when considering the wedge off-axis calculation and the level was similar to that of the treatment planning system using other conventional irradiation techniques.
Assuntos
Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/métodos , Imagens de Fantasmas , SoftwareRESUMO
PURPOSE: A multi-institutional study was performed to identify the impact of different independent dose verification programs on independent dose verification software program. METHODS: Data for 1,543 treatment fields were collected in three institutions. RADCALC and Simple MU Analysis (Simple MU) using the Clarkson-based algorithm were used. RADCALC needs the input of radiological path length (RPL) from radiotherapy treatment planning systems (RTPSs) (Eclipse or Pinnacle3). The Simple MU computes the RPL using CT images independently from the RTPSs. Ion-chamber measurements were performed for commissioning the two programs and the RTPSs. Next, the results of the two programs were compared to the RTPSs obtained in the clinically-approved plans in all three institutions. RESULTS: The commissioning results showed ±1.5% variation in the ion-chamber measurements and there was slight difference between the institutions. The RADCALC (0.9±2.2%) and the Simple MU (1.7±2.1%) results showed a slight systematic difference. Pinnacle3 computed longer RPLs because it used CT-physical density tables. Thus, there was an impact on the accuracy in the treatment plans involving bone and other high-density materials. CONCLUSION: Dose calculation algorithms in different dose verification programs provided similar results. However, care must be taken because different RPL calculation methods in the RTPSs may affect dose difference between different independent dose verification programs by 1%.
Assuntos
Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/métodos , Software , Humanos , Tomografia Computadorizada por Raios XRESUMO
PURPOSE: To present the dosimetric characterization of a multileaf collimator (MLC) for a new four-dimensional image-guided radiotherapy system with a gimbaled x-ray head, MHI-TM2000. METHODS: MHI-TM2000 has an x-ray head composed of an ultrasmall linear accelerator guide and a system-specific MLC. The x-ray head can rotate along the two orthogonal gimbals (pan and tilt rotations) up to +/- 2.5 degrees, which swings the beam up to +/- 41.9 mm in each direction from the isocenter on the isocenter plane perpendicular to the beam. The MLC design is a single-focus type, has 30 pairs of 5 mm thick leaves at the isocenter, and produces a maximum field size of 150 x 150 mm2. Leaf height and length are 110 and 260 mm, respectively. Each leaf end is circular, with a radius of curvature of 370 mm. The distance that each leaf passes over the isocenter is 77.5 mm. Radiation leakage between adjacent leaves is minimized by an interlocking tongue-and-groove (T&G) arrangement with the height of the groove part 55 mm. The dosimetric characterizations including field characteristics, leaf position accuracy, leakage, and T&G effect were evaluated using a well-commissioned 6 MV photon beam, EDR2 films (Kodak, Rochester, NY), and water-equivalent phantoms. Furthermore, the field characteristics and leaf position accuracy were evaluated under conditions of pan or tilt rotation. RESULTS: The differences between nominal and measured field sizes were within +/- 0.5 mm. Although the penumbra widths were greater with wider field size, the maximum width was < 5.5 mm even for the fully opened field. Compared to the results of field characteristics without pan or tilt rotation, the variation in field size, penumbra width, flatness, and symmetry was within +/- 1 mm/l% at the maximum pan or tilt rotational angle. The leaf position accuracy was 0.0 +/- 0.1 mm, ranging from -0.3 to 0.2 mm at four gantry angles of 0 degrees, 90 degrees, 180 degrees, and 270 degrees with and without pan or tilt rotation. The interleaf leakage was up to 0.21%, whereas the intraleaf leakage was < 0.12%. T&G decreased the doses by 10.7%, on average. CONCLUSIONS: This study demonstrated that MHI-TM2000 has the capability for high leaf position accuracy and low leakage, leading to highly accurate intensity-modulated radiotherapy delivery. Furthermore, substantial changes in the dosimetric data on field characteristics and leaf position accuracy were not observed even at the maximum pan or tilt rotation.
Assuntos
Radioterapia/instrumentação , Radiometria , Radioterapia/métodos , Dosagem Radioterapêutica , RotaçãoRESUMO
The Patterns of Care Study (PCS) conducted a nationwide audit survey in order to establish the national practice process of radiation therapy for small-cell lung cancer (SCLC) and examined the influence of institutional stratification on the process of care in Japan. The PCS randomly sampled institutions and patients using a two-stage cluster method and surveyed the process of radiation therapy for 174 stage I-III SCLC patients according to the category of institution, stratified as follows: A1, academic institutions treating > or = 300 patients a year; A2, <300 patients; B1, non-academic institutions treating > or = 120 patients a year; and B2, <120 patients. Karnofsky performance status distributions showed significant variance by stratification of institutions (P=0.013). Patients treated on an outpatient basis accounted for 32% in A1, 23% in A2, 8% in B1, but only 5% in B2 (P=0.007). A photon energy > or = 10 MV was used for 87% of patients in A1, 69% in A2, 54% in B1 and 23% in B2 (P=0.001). Contralateral hilus was irradiated for 11% of patients in A1, 17% in A2, 29% in B1 and 3% in B2 (P=0.001). Field size reduction during the treatment course was done for 77% of patients in A1, 54% in A2, 60% in B1 and 42% in B2 (P=0.007). Ninety-two percent of patients received combined chemotherapy and radiation therapy, and the most frequently used drugs were etoposide (91%) and cisplatin (69%). The results of clinical studies on SCLC had favorably penetrated into the clinical practice. However, the stratification of institutions significantly affected the process of radiation therapy in Japan.